Edivoxetine Hydrochloride

盐酸依地西汀

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameEdivoxetine Hydrochloride
Drug Alias Name依地西汀edivoxetinumedivoxetina艾地西汀LY-2216684 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNorepinephrine reuptake inhibitors
TargetsNorepinephrine transporter
Therapy Area/IndicationsAttention Deficit Disorder with HyperactivityDepressive Disorder, Major
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[34] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesSuzhou Xikro Pharmaceutical Co LtdCatalent Pharma SolutionsEli Lilly And Company +[5] 
Inactive CompaniesN/A
Active IndicationsAttention Deficit Disorder with Hyperactivity
Inactive IndicationsDepressive Disorder, Major

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG